0GP7

Medivir Ab (0GP7)

Medivir Ab

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0GP7

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/01/15	16:45	PR Newswire (US)	Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox	LSE:0GP7	Medivir Ab
2024/01/04	16:47	PR Newswire (US)	Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	LSE:0GP7	Medivir Ab
2023/12/19	16:54	PR Newswire (US)	Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan	LSE:0GP7	Medivir Ab
2023/12/13	19:12	PR Newswire (US)	Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval	LSE:0GP7	Medivir Ab
2023/12/06	20:20	PR Newswire (US)	Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway	LSE:0GP7	Medivir Ab
2023/12/06	16:44	PR Newswire (US)	Medivir to present at the Carlsquare Equity Research Investor Day	LSE:0GP7	Medivir Ab
2023/12/01	19:32	PR Newswire (US)	Bulletin from Extraordinary General Meeting in Medivir AB (publ)	LSE:0GP7	Medivir Ab
2023/11/27	17:52	PR Newswire (US)	Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC	LSE:0GP7	Medivir Ab
2023/11/22	16:46	PR Newswire (US)	Medivir to present at the Redeye Life Science Day	LSE:0GP7	Medivir Ab
2023/11/21	16:48	PR Newswire (US)	Medivir to present at the Erik Penser Bank Company Event	LSE:0GP7	Medivir Ab
2023/11/13	17:49	PR Newswire (US)	Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA	LSE:0GP7	Medivir Ab
2023/11/08	05:50	PR Newswire (US)	Notice of Extraordinary General Meeting in Medivir AB (publ)	LSE:0GP7	Medivir Ab
2023/10/27	16:01	PR Newswire (US)	MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023	LSE:0GP7	Medivir Ab
2023/10/25	15:46	PR Newswire (US)	Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday	LSE:0GP7	Medivir Ab
2023/10/23	15:48	PR Newswire (US)	Nomination Committee of Medivir appointed	LSE:0GP7	Medivir Ab
2023/10/20	22:29	PR Newswire (US)	Change in Medivir's Board of Directors	LSE:0GP7	Medivir Ab
2023/05/17	01:38	PR Newswire (US)	Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023	LSE:0GP7	Medivir Ab
2023/05/04	23:55	PR Newswire (US)	Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)	LSE:0GP7	Medivir Ab
2023/05/04	23:25	PR Newswire (US)	Resolutions at the Annual General Meeting in Medivir on 4 May 2023	LSE:0GP7	Medivir Ab
2023/04/27	16:06	PR Newswire (US)	MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023	LSE:0GP7	Medivir Ab
2023/04/17	16:30	PR Newswire (US)	Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination	LSE:0GP7	Medivir Ab
2023/04/04	18:03	PR Newswire (US)	Medivir 2022 Annual Report published	LSE:0GP7	Medivir Ab
2023/03/31	19:25	PR Newswire (US)	Notice of Annual General Meeting of Medivir AB (publ)	LSE:0GP7	Medivir Ab
2023/03/17	17:01	PR Newswire (US)	Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR	LSE:0GP7	Medivir Ab
2023/03/14	17:18	PR Newswire (US)	First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®	LSE:0GP7	Medivir Ab
2023/03/09	00:08	PR Newswire (US)	Medivir to present at the Stockholm Corporate Finance Life Science Day	LSE:0GP7	Medivir Ab
2023/02/23	17:03	PR Newswire (US)	Medivir to present at the Erik Penser Bank Healthcare Day	LSE:0GP7	Medivir Ab
2023/02/21	17:54	PR Newswire (US)	Pia Baumann takes up her position as Chief Medical Officer	LSE:0GP7	Medivir Ab
2023/02/20	19:04	PR Newswire (US)	Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC	LSE:0GP7	Medivir Ab
2023/02/15	17:15	PR Newswire (US)	MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2022	LSE:0GP7	Medivir Ab